The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)
- PMID: 31932455
- PMCID: PMC7056529
- DOI: 10.1158/0008-5472.CAN-19-2850
The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)
Abstract
Repeated exposure to the acute proinflammatory environment that follows ovulation at the ovarian surface and distal fallopian tube over a woman's reproductive years may increase ovarian cancer risk. To address this, analyses included individual-level data from 558,709 naturally menopausal women across 20 prospective cohorts, among whom 3,246 developed invasive epithelial ovarian cancer (2,045 serous, 319 endometrioid, 184 mucinous, 121 clear cell, 577 other/unknown). Cox models were used to estimate multivariable-adjusted HRs between lifetime ovulatory cycles (LOC) and its components and ovarian cancer risk overall and by histotype. Women in the 90th percentile of LOC (>514 cycles) were almost twice as likely to be diagnosed with ovarian cancer than women in the 10th percentile (<294) [HR (95% confidence interval): 1.92 (1.60-2.30)]. Risk increased 14% per 5-year increase in LOC (60 cycles) [(1.10-1.17)]; this association remained after adjustment for LOC components: number of pregnancies and oral contraceptive use [1.08 (1.04-1.12)]. The association varied by histotype, with increased risk of serous [1.13 (1.09-1.17)], endometrioid [1.20 (1.10-1.32)], and clear cell [1.37 (1.18-1.58)], but not mucinous [0.99 (0.88-1.10), P-heterogeneity = 0.01] tumors. Heterogeneity across histotypes was reduced [P-heterogeneity = 0.15] with adjustment for LOC components [1.08 serous, 1.11 endometrioid, 1.26 clear cell, 0.94 mucinous]. Although the 10-year absolute risk of ovarian cancer is small, it roughly doubles as the number of LOC rises from approximately 300 to 500. The consistency and linearity of effects strongly support the hypothesis that each ovulation leads to small increases in the risk of most ovarian cancers, a risk that cumulates through life, suggesting this as an important area for identifying intervention strategies. SIGNIFICANCE: Although ovarian cancer is rare, risk of most ovarian cancers doubles as the number of lifetime ovulatory cycles increases from approximately 300 to 500. Thus, identifying an important area for cancer prevention research.
©2020 American Association for Cancer Research.
Conflict of interest statement
Figures


References
-
- Fathalla MF. Incessant ovulation--a factor in ovarian neoplasia? Lancet 1971;2(7716):163. - PubMed
-
- Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91(17):1459–67. - PubMed
-
- Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1997;89(13):932–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA016087/CA/NCI NIH HHS/United States
- C570/A16491 /CRUK_/Cancer Research UK/United Kingdom
- MR/N003284/1/MRC_/Medical Research Council/United Kingdom
- UM1 CA182934/CA/NCI NIH HHS/United States
- G1000143/MRC_/Medical Research Council/United Kingdom
- P30 ES000260/ES/NIEHS NIH HHS/United States
- 1000143/MRC_/Medical Research Council/United Kingdom
- K22 CA193860/CA/NCI NIH HHS/United States
- R01 CA039742/CA/NCI NIH HHS/United States
- G0401527/MRC_/Medical Research Council/United Kingdom
- UM1 CA186107/CA/NCI NIH HHS/United States
- R01 CA077398/CA/NCI NIH HHS/United States
- R01 CA047988/CA/NCI NIH HHS/United States
- R01 HL080467/HL/NHLBI NIH HHS/United States
- U01 CA182913/CA/NCI NIH HHS/United States
- Z01 ES044005/ImNIH/Intramural NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- 14136/CRUK_/Cancer Research UK/United Kingdom
- Z01 CP010128/ImNIH/Intramural NIH HHS/United States
- R01 HL043851/HL/NHLBI NIH HHS/United States
- K05 CA154337/CA/NCI NIH HHS/United States
- C8221/A19170 /CRUK_/Cancer Research UK/United Kingdom
- MR/M012190/1/MRC_/Medical Research Council/United Kingdom
- UM1 CA182913/CA/NCI NIH HHS/United States
- RC1 HL099355/HL/NHLBI NIH HHS/United States
- ZIA CP010128/ImNIH/Intramural NIH HHS/United States
- P30 CA071789/CA/NCI NIH HHS/United States
- 001/WHO_/World Health Organization/International
- U01 CA164973/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical